SCHEMBL20875996

SCHEMBL20875996

COc1ccc(CN2CC(CO)C(c3ccccc3)C2=O)cc1

nearest known ligand 0.53

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 2/20 0.49
▸ KMT2A Q03164 2/20 0.49
▸ SIGMAR1 Q99720 3/20 0.46
▸ SIRT2 Q8IXJ6 1/20 0.45
▸ SIRT1 Q96EB6 1/20 0.45
▸ PKM P14618 1/20 0.45
▸ MMP1 P03956 1/20 0.44
▸ MMP13 P45452 1/20 0.44
▸ GRM2 Q14416 1/20 0.44
▸ GSK3B P49841 1/20 0.43
▸ PDE4A P27815 1/20 0.43
▸ PDE4B Q07343 1/20 0.43
▸ PDE4C Q08493 1/20 0.43
▸ PDE4D Q08499 1/20 0.43
▸ ALDH1A1 P00352 2/20 0.43
▸ LMNA P02545 1/20 0.43
▸ RAB9A P51151 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20875995 1.00 MEN1 (0.49) MEN1KMT2ASIGMAR1SIRT2SIRT1
SCHEMBL22279886 1.00 MEN1 (0.49) MEN1KMT2ASIGMAR1SIRT2SIRT1
SCHEMBL22279632 0.87 HPGD (0.49) MEN1KMT2AALDH1A1
SCHEMBL20875927 0.87 HPGD (0.49) MEN1KMT2AALDH1A1
SCHEMBL20875928 0.87 HPGD (0.49) MEN1KMT2AALDH1A1
SCHEMBL20875914 0.83 MEN1 (0.52) MEN1KMT2ASIGMAR1SIRT2SIRT1
SCHEMBL22279815 0.81 MEN1 (0.53) MEN1KMT2ASIGMAR1SIRT2SIRT1
SCHEMBL20875900 0.81 MEN1 (0.52) MEN1KMT2ASIGMAR1SIRT2SIRT1
SCHEMBL20875902 0.81 MEN1 (0.52) MEN1KMT2ASIGMAR1SIRT2SIRT1
SCHEMBL30892045 0.77 HCRTR1 (0.40) MEN1KMT2APKMMMP1MMP13

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11180479-B2 Antiviral compounds HAPLOGEN GMBH (AT) 2021-11-23 — — US disclosed
EP-3692035-A1 ANTIVIRAL COMPOUNDS Haplogen GmbH (AT) 2020-08-12 — — EP disclosed
US-20200239446-A1 ANTIVIRAL COMPOUNDS LUNIS CONSULTING GMBH (AT) 2020-07-30 — — US disclosed
WO-2019068841-A1 ANTIVIRAL COMPOUNDS HAPLOGEN GMBH (AT) 2019-04-11 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11180479-B2 Antiviral compounds PLA2G1B, PLA2G4A, PLA2G4C MEN1 4027/4885KMT2A 4046/4885SIGMAR1 2247/4885
US-20200239446-A1 ANTIVIRAL COMPOUNDS PLA2G1B, PLA2G4A, PLA2G4C MEN1 4027/4885KMT2A 4046/4885SIGMAR1 2247/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback